Production (Stage)
Integrated Biopharma, Inc.
INBP
$0.29
-$0.0135-4.45%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.67% | 3.18% | -0.47% | -0.70% | -0.75% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.67% | 3.18% | -0.47% | -0.70% | -0.75% |
| Cost of Revenue | 1.21% | -0.25% | -1.62% | -0.38% | 1.09% |
| Gross Profit | 49.94% | 51.64% | 13.53% | -4.36% | -19.79% |
| SG&A Expenses | -3.12% | -2.79% | -6.01% | -7.82% | -8.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.90% | -0.44% | -1.95% | -0.96% | 0.34% |
| Operating Income | 2,645.83% | 478.33% | 2,108.33% | 109.17% | -115.03% |
| Income Before Tax | 3,085.71% | 494.31% | 2,052.63% | 168.00% | -114.86% |
| Income Tax Expenses | 1,083.02% | 3,193.75% | 304.17% | 16.42% | 105.32% |
| Earnings from Continuing Operations | 1,181.03% | 341.04% | 841.38% | 429.41% | -108.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1,181.03% | 341.04% | 841.38% | 429.41% | -108.17% |
| EBIT | 2,645.83% | 478.33% | 2,108.33% | 109.17% | -115.03% |
| EBITDA | 788.11% | 3,175.86% | 199.20% | 21.02% | -70.78% |
| EPS Basic | 1,164.10% | 338.76% | 815.00% | 408.33% | -108.21% |
| Normalized Basic EPS | 3,084.62% | 505.26% | 2,037.50% | 154.55% | -114.94% |
| EPS Diluted | 1,156.41% | 337.98% | 815.00% | 408.33% | -108.21% |
| Normalized Diluted EPS | 2,620.00% | 490.91% | 2,257.14% | 147.62% | -118.75% |
| Average Basic Shares Outstanding | 0.47% | 0.42% | 0.49% | 0.39% | 0.31% |
| Average Diluted Shares Outstanding | 1.63% | 0.41% | -0.45% | -0.99% | -0.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |